Anti-Endothelial Cell Autoantibodies and Soluble Markers of Endothelial Cell Dysfunction in Systemic Lupus Erythematosus

JOEL CONSTANS, REMY DUPUY, ANDREW D. BLANN, FRANCOIS RESPLANDY, MARTINE SEIGNEUR, MARTINE RENARD, MAÏTE LONGY-BOURSIER, THIERRY SCHAEVERBEKE, VIVIANE GUÉRIN, MICHEL R. BOISSEAU, and CLAUDE CONRI

ABSTRACT. ***Objective.*** To determine if anti-endothelial cell antibodies (AECA) and plasma markers of endothelial cell function are related to disease severity in systemic lupus erythematosus (SLE).

Methods. We measured AECA by human umbilical vein endothelial cell binding, endothelial markers von Willebrand factor, soluble thrombomodulin, and soluble E-selectin by ELISA, and disease severity by SLEDAI and SLICC/ACR in 35 patients with SLE.

Results. Despite high levels of IgG AECA ($p = 0.001$) and von Willebrand factor ($p = 0.0007$) compared to 21 healthy controls, we found a positive correlation only between IgG AECA and the SLEDAI index ($r = 0.393$, $p = 0.021$).

Conclusion. IgG AECA seem to be related to disease activity in SLE, possibly in a pathogenic role. Conversely, plasma markers of endothelial cell damage seem to be an epiphenomenon and may simply be related to excess inflammation. (J Rheumatol 2003;30:1963–6)

Key Indexing Terms:
ENDOTHELIUM
SYSTEMIC LUPUS ERYTHEMATOSUS
ANTI-ENDOTHELIAL ANTIBODIES
VON WILLEBRAND FACTOR

Systemic lupus erythematosus (SLE) is a progressive systemic disease that frequently deteriorates clinically to vascular involvement and thrombotic complications. In many cases these complications seem to be related to the presence of antiphospholipid antibodies, high titers of antinuclear and anti-DNA, or anti-soluble nuclear antigen antibodies[1]. Anti-endothelial cell antibodies (AECA), directed towards antigens on human umbilical vein endothelial cells (HUVEC) have also been found in the serum of SLE patients[2,3]. It is unclear whether AECA have a pathogenic role in the clinical manifestations, especially vascular events, or whether they are simply the result of polyclonal stimulation or cross-reactions with non-endothelial antigens.

From the Service de Médecine Interne et Pathologie Vasculaire, Hôpital Saint-André, the Laboratoire d'Hématologie, Université de Bordeaux II, and the Service de Rhumatologie, Hôpital Pellegrin-Tondu, Bordeaux, France; and the Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK.

J. Constans, MD, Service de Médecine Interne et Pathologie Vasculaire, Hôpital Saint-André; R. Dupuy, MD, Laboratoire d'Hématologie, Université de Bordeaux II; A.D. Blann, MD, Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital; F. Resplandy, MD; M. Seigneur, MD; M. Renard, MD, Laboratoire d'Hématologie, Université de Bordeaux II; M. Longy-Boursier, MD, Service de Médecine Interne, Hôpital Saint-André; T. Schaeverbeke, MD, Service de Rhumatologie, Hôpital Pellegrin-Tondu; V. Guérin, MD; M.R. Boisseau, MD, Laboratoire d'Hématologie, Université de Bordeaux II; C. Conri, MD, Service de Médecine Interne et Pathologie Vasculaire, Hôpital Saint-André.

Address reprint requests to Dr. J. Constans, Service de Médecine Interne et Pathologie Vasculaire, Hôpital Saint-André, 1 rue Jean Burguet, 33075 Bordeaux, France. E-mail: joel.constans@chu-bordeaux.fr

Submitted September 12, 2002; revision accepted January 24, 2003.

SLE is also associated with elevated concentrations of various soluble markers of endothelial cell function, including von Willebrand factor, soluble thrombomodulin, and soluble E-selectin[4-15]. Increased levels of these markers imply damage to and/or activation of the endothelium and can be predictive of adverse outcome such as myocardial infarction and stroke. Despite these findings, the significance of the relationship between circulating markers, potentially cytotoxic autoantibodies, and the clinical activity of SLE remains controversial[14-16].

To help clarify these points, we hypothesized that in patients with SLE, there would be a clear relationship between plasma markers of endothelial damage, autoantibodies to endothelial cells, and the clinical severity of disease.

MATERIALS AND METHODS

Patients. Thirty-five patients were recruited during a one-year period in a University Hospital: all fulfilled the American College of Rheumatology criteria for SLE[17] (32 women, 3 men, mean age 37.8 ± 12.5). Visceral involvement was present in 20 patients [kidney in 9, central nervous system (CNS) in 4, cardiovascular in 4, lung in 3]. Kidney disease was defined as proteinuria above 200 mg/24 h; CNS was defined as clinical CNS disease symptoms and magnetic resonance imaging evidence of CNS vascular disease; cardiovascular involvement was defined as deep venous thrombosis or echographic evidence of segmental abnormal kinetics or valvular involvement; and lung disease was defined as interstitial disease as assessed by chest computer tomography (CT) scan and no other cause of lung disease than SLE. The other 15 patients only had cutaneous or articular manifestations. Six patients were untreated at the time of sampling, 8 were taking immunosuppressive drugs and 29 were taking steroids (> 20 mg/day taken by 12 patients and < 20 mg/day taken by 17). The disease

Personal, non-commercial use only. The Journal of Rheumatology Copyright © 2003. All rights reserved.

Downloaded on April 19, 2024 from www.jrheum.org

activity of SLE at sampling was quantified in 34 of the 35 patients by using the SLE Disease Activity Index (SLEDAI)[18], and the cumulative severity of SLE was quantified by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index in 21 of the 35 patients[19]. To avoid biases in the interpretation of soluble endothelial markers, patients with creatininemia above 150 µM/l were excluded. No patient had diabetes mellitus or infection at sampling but the duration of SLE was variable among patients. The patients were sampled once and clinical status was determined at the time of sampling. Twenty-one age-matched healthy subjects (11 women, 10 men, mean age 38.7 ± 17.6) were used as a control group.

Laboratory measurements. Blood was sampled after informed consent by venous puncture after a 12 h fast. AECA were measured by enzyme immunoassay on cultured HUVEC according to established criteria[20]. The endothelial cells were extracted according to Jaffe's method then cultured in a GIBCO 199 supplemented with 10% fetal calf serum to confluence in 96-well microplates. Cells were fixed with 0.1% glutaraldehyde for 10 min at 4°C. Then the plates were washed 3 times with phosphate buffer saline (PBS) supplemented with 1% human serum albumin (HSA). To avoid nonspecific fixation, blocking was carried out with 3% HSA for 2 h at 37°C. Then the plates were washed 3 times with PBS/HSA 1%. PBS/HSA 0.5% was used as a negative control. Then the cells were incubated with the serum diluted to 1/800 (IgA), 1/1600 (IgM) and 1/3200 (IgG) in PBS/HSA for 2 h at 37°C. The plates were washed 3 times with PBS/HSA 1%. Then plates were incubated with peroxidase-labeled F(ab')2 diluted to 1/2000 for anti-IgA and anti-IgM and to 1/1000 for IgG in PBS/HSA 0.5%. The plates were washed 3 times with PBS/HSA 1%, then twice in PBS only. Plates were then incubated with the substrate orthophenylene diamine (OPD) 2.2 mg/l in phosphate citrate buffer, pH 5 with hydrogen peroxide 1/2400 for 5 min at room temperature. The reaction was stopped with sulfuric acid 3 mmol/l and the optical densities (OD) were read during the following 10 min to 1 h. Results were expressed as the ratio of the patient's OD: positive control OD. The cut-off value (positivity level) was chosen as mean + 3 standard deviations (SD) of the ratios found in the controls. Sera found to be positive were later used as positive controls on subsequent plates.

Plasma thrombomodulin, von Willebrand factor, and soluble E-selectin were measured in citrated plasma by established commercial ELISA (Asserachrom Stago Diagnostica, France and Dako, Denmark). The intraassay coefficents of variation of these assays are < 5%. Interassay coefficents are < 10%. Antinuclear antibodies were determined by immunofluorescence on HEp2 cells; anti-DNA and anti-ECT (anti-soluble antigens) were determined by ELISA.

Data analysis. Statistical analysis was performed using student's t test (data distributed normally), the Mann-Whitney U test (data distributed non-normally), and Spearman's correlation test (Microsoft Excel 4 software and Minitab Release 12).

RESULTS

Cross-sectional data (Table 1). Compared to controls, SLE patients had a significantly higher IgG AECA ratio. Twenty-one of the 35 SLE patients had positive IgG AECA while none of the controls was positive for IgG AECA. Of the plasma markers, only von Willebrand factor was higher in the patients relative to the controls. The 9 patients with kidney disease (but creatininemia < 150 µmol/l) had higher levels of soluble thrombomodulin than the 26 who were free of hypercreatininemia: 53 ± 16 ng/ml versus 34 ± 10 ng/ml, $p = 0.001$. The 19 patients with active SLE (SLEDAI > 6) had higher AECA than those 16 whose SLEDAI was < 6: 1.28 ± 0.77 versus 0.58 ± 0.46, $p = 0.004$. Eighteen percent of patients had a positive result for antiphospholipid antibodies (anti-cardiolipin or anti-ß$_2$-glycoprotein I ELISA).

Correlations within patients with SLE (Table 2). We found positive correlations between IgG AECA and the SLEDAI ($r = 0.53$, $p < 0.0001$) (Figure 1), and between soluble thrombomodulin and SLICC ($r = 0.465$, $p = 0.045$). However, there were no statistically significant correlations between any of the AECA titers and levels of the plasma markers.

DISCUSSION

Our data confirm the presence of AECA and raised von Willebrand factor in SLE patients. In previous studies, the prevalence of AECA in SLE varied from 0 to 80%[2,3,21-23]. Such differences among the studies may arise from the absence of standardization of the measurement methods and from differences among the study populations. Standardization of AECA measurement is in process[24]. Various indices have also been used to assess SLE activity. We used those (SLEDAI and SLICC/ACR) that seemed to us as the best validated and most currently used differentiating activity and damage scores. However the SLICC/ACR index may not only reflect damage from SLE but also from treatment (for example visual loss may come from SLE but also from steroid-associated cataracts). The only endothelial marker that we found to differ significantly in this sample of patients compared with controls was von Willebrand factor, a marker of endothelial damage or activation[5].

Our results show that IgG AECA are present in SLE patients and correlate with disease activity. Most of our patients were receiving treatment and this may explain the lack of increase in soluble thrombomodulin and soluble E-selectin. However, although levels were not significantly raised relative to controls, we found a correlation between soluble thrombomodulin and SLICC but not SLEDAI index, suggesting a relationship between soluble thrombomodulin and damage but not with activity of the disease. Conversely, we, like others[2,21,25], found a correlation between IgG AECA and the activity of the disease. The epitopes recognized by AECA have not been clearly identified so far although a close cross-reactivity has been shown between AECA and anti-cardiolipin or anti-ß$_2$-glycoprotein I antibodies[26-29]. Hill found anti-endothelial cell antibodies in half of the patients with primary antiphospholipid syndrome (APS) and two-thirds of 32 SLE patients, and also showed that differences exist when using HUVEC or human microvascular endothelial cells for the detection of AECA[30]. A direct pathogenic role has been suggested for AECA in APS, Wegener's granulomatosis, and in scleroderma[27,31] since IgG AECA are able in these conditions to enhance the expression of adhesion molecules (vascular cellular adhesion molecule-1, E-selectin) on endothelial cells. In SLE, as in vasculitides, IgG AECA have been shown to be cytotoxic towards endothelial cells[3,32]. Antiphospholipid antibodies (aPL) may be responsible for vascular lesions in many patients: SLE patients with aPL have been found to have increased thrombin

Personal, non-commercial use only. The Journal of Rheumatology Copyright © 2003. All rights reserved.

Downloaded on April 19, 2024 from www.jrheum.org

Table 1. Anti-endothelial cell antibodies and soluble endothelial cell markers in patients and controls. Data are presented as mean ± standard deviation or median and interquartile range.

	SLE Patients	Controls	p
IgA AECA ratio	0.640 (0.443–0.930)	0.535 (0.391–0.846)	0.3884
IgM AECA ratio	0.373 (0.261–0.709)	0.470 (0.270–627)	0.9541
IgG AECA ratio	0.744 (0.468–1.394)	0.211 (0.133–0.325)	< 0.0001
Von Willebrand factor (IU/dl)	130 ± 23	103 ± 35	0.0007
Soluble thrombomodulin (ng/ml)	42 ± 21	37 ± 11	0.175
Soluble E-selectin (ng/ml)	57 ± 38	51 ± 18	0.383

AECA: anti-endothelial cell antibodies.

Table 2. Spearman correlations and p values between AECA, endothelial cell markers, and indices of disease activity in patients with SLE.

	SLEDAI		SLICC	
	r	p	r	p
IgA AECA	0.18	0.297	–0.301	0.197
IgM AECA	0.03	0.878	0.035	0.88
IgG AECA	0.53	0.001	–0.28	0.23
VWf	–0.17	0.47	0.23	0.26
STM	0.24	0.33	0.035	0.89
Soluble E-selectin	0.15	0.55	0.023	0.92



Figure 1. Correlation between anti-endothelial cell IgG and SLEDAI.

generation following microvascular injury *ex vivo*[33] and prothrombic state assessed by both increase in von Willebrand factor and tissue plasminogen activator when they had aPL[34]. However, more data are needed to establish such a pathogenic role that is not suggested from our results. In SLE patients the situation is complicated by the presence of vascular lesions and inflammation, perhaps related to aPL[1]. The interpretation of markers of endothelial dysfunction that can increase in both conditions[35-39] is difficult. We excluded patients with renal insufficiency but not those with nephrotic syndrome. Heavy proteinuria may increase the concentration of von Willebrand factor so that a bias might be present that affects the interpretation of any correlation. Part of vascular dysfunction may be immune related (perhaps due to cytokines) and perhaps caused by AECA or aPL, while part may be related to enhanced atherogenesis, accelerated by dyslipidemia or steroid therapy. Additional experiments are required to clarify these issues.

We found increased levels of AECA and von Willebrand factor, but no correlation between them, and also a correlation between AECA and disease activity. Raised von Willebrand factor may be an epiphenomenon unrelated directly to the disease process, but the small number of patients as well as the heterogeneous nature of SLE vascular injury may also explain this absence of correlation. Serial testing was not available in our study but would provide more potent data to clarify this lack of correlation. Lack of correlation between AECA and von Willebrand factor is reminiscent of a similar study in diabetes. Petty, *et al*[40] found a correlation between raised von Willebrand factor and diabetic retinopathy (a possible index of disease activity) but no correlation with increased levels of IgG or IgM AECA. This therefore underlines the difficulty in interpreting the roles of AECA and von Willebrand factor in inflammatory (e.g., SLE) and non-inflammatory (e.g., diabetes) vascular diseases. Our data do not support the use of anti-endothelial cell antibodies as a measure of disease activity.

REFERENCES

1. Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Arthritis Rheum 1996;39:9-22.
2. Cines DB, Lyss AP, Reeber M, Bina B, De Horatius RJ. Presence of complement fixing anti-endothelial cell antibodies in systemic lupus erythematosus. J Clin Invest 1984;73:611-25.
3. Penning C, French M, Rowell N, Hughes P. Antibody dependent cellular toxicity to human vascular endothelium in systemic lupus erythematosus. J Clin Lab Immunol 1985;17:125-30.
4. Boehme MWJ, Nawroth RP, Kling E, et al. Serum thrombomodulin, a novel marker of disease activity in systemic lupus erythematosus. Arthritis Rheum 1994;37:572-7.
5. Blann AD, Hopkins J, Winkles J, Wainwright AC. Plasma and serum von Willebrand factor antigen concentrations in connective tissue disorders. Ann Clin Biochem 1992;29:67-71.
6. Kawakami M, Kitani A, Hara A, et al. Plasma thrombomodulin and alpha 2 plasmin inhibitor-plasmin complex are elevated in active systemic lupus erythematosus J Rheumatol 1992;19:1704-9.
7. Schinco P, Borchiellini A, Tamponi G, et el. Lupus anticoagulant

Personal, non-commercial use only. The Journal of Rheumatology Copyright © 2003. All rights reserved.

Downloaded on April 19, 2024 from www.jrheum.org

and thrombosis: role of von Willebrand factor multimeric forms. Clin Exp Rheumatol 1997;15:5-10.
8. Doria A, Ghirardello A, Boscaro M, et al. Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus- relationship with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy. Rheumatol Int 1995;14:207-11.
9. Matsuda J, Msukamoto M, Gohchi K, et al. Effect of total body cold exposure on plasma concentrations of von Willebrand factor, endothelin-1 and thrombomodulin in systemic lupus erythematosus patients with or without Raynaud's phenomenon. Acta Haematol 1992;88:189-93.
10. Lai KK, Leung JK, Lai KB, Wong KC, Lai CKW. Upregulation of adhesion molecule expression on endothelial cells by anti-DNA auto-antibodies in systemic lupus erythematosus. Clin Immun Immunopathol 1996;81:229-38.
11. Boehme MWJ, Schmidt WH, Youinou P, Stremmel WR, Gross WL. Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides. Am J Med 1996;101:387-93.
12. Belmont H, Guyon J, Giorno R, Abranson S. Upregulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. Arthritis Rheum 1994;37:376-83.
13. Nyberg F, Acevedo F, Stephanson E. Different patterns of soluble adhesion molecules in systemic and cutaneous lupus erythematosus. Exp Dermatol 1997;6:230-5.
14. Mrowka C, Sieberth H. Circulating adhesion molecules ICAM-1, VCAM-1 and E-selectin in systemic vasculitis: marked differences between Wegener's granulomatosis and systemic lupus erythematosus. Clin Invest 1994:72:762-8.
15. Spronk PE, Bootsma H, Huitema MG, Limburg PC, Kallenberg CG. Levels of soluble VCAM-1, soluble ICAM-1 and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE), a long time prospective study. Clin Exp Immunol 1994;97:439-44.
16. Janssen BA, Luqmani RA, Gordon C, et al. Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis. Br J Rheumatol 1994;33:1112-6.
17. Tan EM, Cohen AS, Fries JF, Masi AT, Shane DJ, Rothfield NF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Committee in prognosis studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
19. Gladman D, Ginzler R, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics / American College of Rheumatology damage index for SLE. Arthritis Rheum 1996;39:363-9.
20. Hashemi S, Smith CD, Izaguirre CA. Anti-endothelial cell antibodies detection and characterization using a cellular enzyme-linked immunosorbent assay. J Lab Clin Med 1987;109:434-40.
21. D'Cruz DP, Houssiau FA, Ramirez G, et al. Antibodies to endothelial cells in systemic lupus erythematosus: a potential marker for nephritis and vasculitis. Clin Exp Immunol 1991;85:254-61.
22. Yoshio T, Masuyana J, Sumiya M, Minota S, Kano S. Anti-endothelial cell antibodies and their relation to pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 1994;21:2058-63.
23. Perry GJ, Elton K, Khouina NA, Chan M, Cameron JS, Frampton G. Anti-endothelial cell antibodies in systemic lupus: correlations with renal injury and circulating markers of endothelial damage. Q J Med 1993;86:727-34.
24. Youinou P, Meroni PL, Khamastha MA, Shoenfeld Y. Standardization programme of the anti-endothelial cell antibody test. Immunol Today 1995;16:563-4.
25. Chan TM, Yu PM, Tsang KLC, Cheng IKP. Endothelial cell binding by human polyclonal anti-DNA antibodies: relationship to disease activity and endothelial functional alterations. Clin Exp Immunol 1995;100:506-13.
26. Song J, Park YB, Lee WK, Lee KH, Lee SK. Clinical associations of anti-endothelial cell antibodies in patients with systemic lupus erythematosus. Rheumatol Int 2000;20:1-7.
27. Vismara A, Meroni PL, Tincani A, et al. Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus. Clin Exp Immunol 1988;74:247-53.
28. Del Papa N, Meroni Pl, Tincani A, et al. Relationship between anti-phospholipid and anti-endothelial antibodies: further characterization of reactivity on resting and cytokine activated endothelial cells. Clin Exp Rheumatol 1992;10:37-42.
29. Cervera R, Khamashta MA, Font J, et al. Anti-endothelial cell antibodies in patients with the anti-phospholipid syndrome. Autoimmunity 1991;11:1-6.
30. Navarro M, Cervera R, Teixido M, et el. Antibodies to endothelial cells and to b2-glycoprotein 1 in the antiphospholipid syndrome: prevalence and isotype distribution. Br J Rheumatol 1996;35:523-38.
31. Hill MB, Philips JL, Hughes P, Greaves M. Anti-endothelial cell antibodies in primary antiphospholipid syndrome and SLE: patterns of reactivity with membrane antigens on microvascular and umbilical venous cell membranes. Br J Haematol 1998;103:416-21.
32. Carvalho D, Savage C, Black CM, Pearson JD. IgG anti-endothelial cell antibodies from scleroderma patients induce leukocytes adhesion to human vascular endothelial cells in vitro: induction of adhesion molecule expression and involvement of endothelium derived cytokines. J Clin Invest 1996;97:111-9.
33. Del Papa N, Meroni PL, Barcellini W, et al. Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in presence of normal peripheral blood mononuclear cells. Clin Immunol Immunopathol 1992;63:267-74.
34. Musial J, Swadzba J, Jankowski M, Grzywacz M, Bazan-Socha S, Szczeklik A. Thrombin generation measured ex vivo following microvascular injury is increased in SLE patients with antiphospholipid-protein antibodies. Thromb Haemost 1997;78:1173-7.
35. Ferro D, Pittoni V, Quintarelli C, et al. Coexistence of antiphospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state. Circulation 1997;95:1425-32.
36. Seigneur M, Dufourcq P, Conri C, et al. Levels of plasma thrombomodulin are increased in atheromatous arterial disease. Thromb Res 1993;71:423-31.
37. Blann AD, Lip GYH. The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coagul Fibrinolysis 1998;9:297-306.
38. Papa ND, Raschi E, Moroni G, et al. Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to endothelial cells and induce a pro-adhesive and pro-inflammatory state in vitro. Lupus 1999;8:423-9.
39. Bordron A, Revelen R, D'Arbonneau F, et al. Functional heterogeneity of anti-endothelial cell antibodies. Clin Exp Immunol 2001;124:492-501.
40. Petty RG, Pottinger BE, Greenwood RM, Pearson JD, Mahler RF. Diabetes is associated with a high incidence of endothelial binding antibodies which do not correlate with retinopathy, von Willebrand factor, angiotensin converting enzyme or C-reactive protein. Diabetes Res 1991;17:115-23.

Personal, non-commercial use only. The Journal of Rheumatology Copyright © 2003. All rights reserved.

Downloaded on April 19, 2024 from www.jrheum.org